Today: 1 May 2026
L3Harris (LHX) stock jumps premarket on Pentagon’s $1 billion Missile Solutions IPO plan
13 January 2026
1 min read

L3Harris (LHX) stock jumps premarket on Pentagon’s $1 billion Missile Solutions IPO plan

NEW YORK, Jan 13, 2026, 08:02 EST — Premarket

  • L3Harris shares surged roughly 10% in premarket, following the U.S. Defense Department’s announcement of a $1 billion investment linked to a missile-unit spin-off.
  • The company announced plans to list its Missile Solutions business on the stock market in the latter half of 2026.
  • Investors await a 9 a.m. ET update call, alongside the company’s earnings report due Jan. 29.

L3Harris Technologies (LHX) shares surged roughly 10% to $376.04 in premarket trading Tuesday following the announcement of its plan to spin off the Missile Solutions unit, supported by a $1 billion U.S. government investment. The defense contractor said it aims for an initial public offering, or IPO, in the latter half of 2026.

The Pentagon announced funding to boost U.S. solid rocket motor capacity — the engines powering missiles post-launch. It labeled this the first-ever “direct-to-supplier” partnership of its kind, with plans for multi-year procurement deals, contingent on congressional approval and funding. “We are fundamentally shifting our approach to securing our munitions supply chain,” Under Secretary Michael Duffey said. U.S. Department of War

Traders faced a packed premarket session as the news broke. U.S. stock index futures dipped modestly early Tuesday, with inflation figures scheduled for release at 8:30 a.m. ET. The quarterly earnings season got underway, led by reports from major banks.

L3Harris revealed the government’s backing will be a $1 billion convertible preferred security—a hybrid that can convert into common stock—once the missile division goes public. The company framed this move around its Aerojet Rocketdyne acquisition, anticipating the unit will bolster programs like PAC-3, THAAD, Tomahawk, and Standard Missile. “We’re taking action to build today’s ‘Arsenal of Freedom,’” CEO Christopher Kubasik stated.

The company said J.P. Morgan Securities will serve as financial adviser, with Vinson & Elkins providing legal counsel on the proposed deal.

L3Harris ended Monday up 1.46% at $340.68, hitting a fresh 52-week high, MarketWatch reported. RTX climbed 2.84%, while Lockheed Martin added 1.53% during the session, the data showed.

The setup is unusual for defense: the government owning an equity stake in a contractor that routinely competes for federal contracts. This has sparked concerns about conflicts of interest and potential regulatory scrutiny. An IPO might also allow the government to cash in on its investment.

The Defense Department has inked a letter of intent laying out investment terms, though it still awaits congressional approval, National Defense Magazine reports. Investors are keenly watching for timing specifics and any updates on capacity ramp-up plans — the crucial factor that shifts this from just a headline to serious earnings potential.

Next on the calendar: an investor update call set for 9:00 a.m. ET Tuesday, ahead of L3Harris’ fourth-quarter 2025 earnings report due Jan. 29.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:13 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Coinbase stock rises as Senate revives CLARITY Act crypto bill — stablecoin rewards in play
Previous Story

Coinbase stock rises as Senate revives CLARITY Act crypto bill — stablecoin rewards in play

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus
Next Story

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Go toTop